These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33096564)

  • 1. The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM.
    Elliott PM
    Cardiovasc Res; 2020 Nov; 116(13):e175-e178. PubMed ID: 33096564
    [No Abstract]   [Full Text] [Related]  

  • 2. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target population for a selective cardiac myosin inhibitor in hypertrophic obstructive cardiomyopathy: Real-life estimation from the French register of hypertrophic cardiomyopathy (REMY).
    Parodi A; Puscas T; Réant P; Donal E; M'Barek Raboudi D; Billon C; Bacher A; El Hachmi M; Wahbi K; Jeunemaître X; Hagège A;
    Arch Cardiovasc Dis; 2024; 117(6-7):427-432. PubMed ID: 38762345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
    Heitner SB; Jacoby D; Lester SJ; Owens A; Wang A; Zhang D; Lambing J; Lee J; Semigran M; Sehnert AJ
    Ann Intern Med; 2019 Jun; 170(11):741-748. PubMed ID: 31035291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
    Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
    Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavacamten decreases maximal force and Ca
    Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW
    Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Maron MS; Masri A; Nassif ME; Barriales-Villa R; Arad M; Cardim N; Choudhury L; Claggett B; Coats CJ; Düngen HD; Garcia-Pavia P; Hagège AA; Januzzi JL; Lee MMY; Lewis GD; Ma CS; Michels M; Olivotto I; Oreziak A; Owens AT; Spertus JA; Solomon SD; Tfelt-Hansen J; van Sinttruije M; Veselka J; Watkins H; Jacoby DL; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Abraham TP;
    N Engl J Med; 2024 May; 390(20):1849-1861. PubMed ID: 38739079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy.
    Pysz P; Rajtar-Salwa R; Smolka G; Olivotto I; Wojakowski W; Petkow-Dimitrow P
    Kardiol Pol; 2021; 79(9):949-954. PubMed ID: 34268723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eighteen-Month Real-World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population.
    Ramonfaur D; Gasperetti A; Blake VE; Rivers B; Kassamali AA; Kasper EK; Barouch LA; Wu KC; Madrazo JA; Carrick RT
    J Am Heart Assoc; 2024 Aug; 13(15):e034069. PubMed ID: 39082420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
    Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I
    Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis.
    Saberi S; Cardim N; Yamani M; Schulz-Menger J; Li W; Florea V; Sehnert AJ; Kwong RY; Jerosch-Herold M; Masri A; Owens A; Lakdawala NK; Kramer CM; Sherrid M; Seidler T; Wang A; Sedaghat-Hamedani F; Meder B; Havakuk O; Jacoby D
    Circulation; 2021 Feb; 143(6):606-608. PubMed ID: 33190524
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
    Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
    J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
    Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O
    Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
    Ho CY; Mealiffe ME; Bach RG; Bhattacharya M; Choudhury L; Edelberg JM; Hegde SM; Jacoby D; Lakdawala NK; Lester SJ; Ma Y; Marian AJ; Nagueh SF; Owens A; Rader F; Saberi S; Sehnert AJ; Sherrid MV; Solomon SD; Wang A; Wever-Pinzon O; Wong TC; Heitner SB
    J Am Coll Cardiol; 2020 Jun; 75(21):2649-2660. PubMed ID: 32466879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
    Cresci S; Bach RG; Saberi S; Owens AT; Spertus JA; Hegde SM; Lakdawala NK; Nilles EK; Wojdyla DM; Sehnert AJ; Wang A
    Circulation; 2024 Feb; 149(7):498-509. PubMed ID: 37961906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.
    Tower-Rader A; Ramchand J; Nissen SE; Desai MY
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Spertus JA; Fine JT; Elliott P; Ho CY; Olivotto I; Saberi S; Li W; Dolan C; Reaney M; Sehnert AJ; Jacoby D
    Lancet; 2021 Jun; 397(10293):2467-2475. PubMed ID: 34004177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
    Chase Cole J; Benvie SF; DeLosSantos M
    Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
    Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
    JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.